BEAM
Price
$29.89
Change
-$0.73 (-2.38%)
Updated
Oct 21, 04:59 PM (EDT)
Capitalization
3.1B
20 days until earnings call
Intraday Buy/Sell Signals
FATE
Price
$1.53
Change
-$0.01 (-0.65%)
Updated
Oct 21, 04:59 PM (EDT)
Capitalization
177.61M
9 days until earnings call
Intraday Buy/Sell Signals
Interact to see
Advertisement

BEAM vs FATE

Header iconBEAM vs FATE Comparison
Open Charts BEAM vs FATEBanner chart's image
Beam Therapeutics
Price$29.89
Change-$0.73 (-2.38%)
Volume$59.93K
Capitalization3.1B
Fate Therapeutics
Price$1.53
Change-$0.01 (-0.65%)
Volume$9.12K
Capitalization177.61M
BEAM vs FATE Comparison Chart in %
BEAM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
FATE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
BEAM vs. FATE commentary
Oct 21, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BEAM is a Hold and FATE is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Oct 21, 2025
Stock price -- (BEAM: $30.62 vs. FATE: $1.54)
Brand notoriety: BEAM and FATE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BEAM: 177% vs. FATE: 49%
Market capitalization -- BEAM: $3.1B vs. FATE: $177.61M
BEAM [@Biotechnology] is valued at $3.1B. FATE’s [@Biotechnology] market capitalization is $177.61M. The market cap for tickers in the [@Biotechnology] industry ranges from $107.45B to $0. The average market capitalization across the [@Biotechnology] industry is $2.07B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BEAM’s FA Score shows that 0 FA rating(s) are green whileFATE’s FA Score has 1 green FA rating(s).

  • BEAM’s FA Score: 0 green, 5 red.
  • FATE’s FA Score: 1 green, 4 red.
According to our system of comparison, both BEAM and FATE are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BEAM’s TA Score shows that 4 TA indicator(s) are bullish while FATE’s TA Score has 6 bullish TA indicator(s).

  • BEAM’s TA Score: 4 bullish, 4 bearish.
  • FATE’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, FATE is a better buy in the short-term than BEAM.

Price Growth

BEAM (@Biotechnology) experienced а +20.60% price change this week, while FATE (@Biotechnology) price change was +10.79% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +8.56%. For the same industry, the average monthly price growth was +22.45%, and the average quarterly price growth was +71.53%.

Reported Earning Dates

BEAM is expected to report earnings on Nov 10, 2025.

FATE is expected to report earnings on Oct 30, 2025.

Industries' Descriptions

@Biotechnology (+8.56% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
BEAM($3.1B) has a higher market cap than FATE($178M). BEAM YTD gains are higher at: 23.468 vs. FATE (-6.667). FATE has higher annual earnings (EBITDA): -161.6M vs. BEAM (-414.33M). BEAM has more cash in the bank: 1.15B vs. FATE (223M). FATE has less debt than BEAM: FATE (81.3M) vs BEAM (155M). BEAM has higher revenues than FATE: BEAM (60.3M) vs FATE (8.47M).
BEAMFATEBEAM / FATE
Capitalization3.1B178M1,740%
EBITDA-414.33M-161.6M256%
Gain YTD23.468-6.667-352%
P/E RatioN/AN/A-
Revenue60.3M8.47M712%
Total Cash1.15B223M516%
Total Debt155M81.3M191%
FUNDAMENTALS RATINGS
FATE: Fundamental Ratings
FATE
OUTLOOK RATING
1..100
27
VALUATION
overvalued / fair valued / undervalued
1..100
14
Undervalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
98
PRICE GROWTH RATING
1..100
40
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
BEAMFATE
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
86%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
N/A
Bullish Trend 2 days ago
73%
MACD
ODDS (%)
Bullish Trend 2 days ago
74%
Bullish Trend 2 days ago
79%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
82%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
82%
Advances
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 7 days ago
85%
Declines
ODDS (%)
Bearish Trend 9 days ago
84%
Bearish Trend 20 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
73%
Bullish Trend 2 days ago
82%
View a ticker or compare two or three
Interact to see
Advertisement
BEAM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
FATE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
ATWAX25.98N/A
N/A
AB Tax-Managed Wealth Apprec Strat A
WEMCX6.17N/A
N/A
Allspring Emerging Growth C
JVMTX29.51N/A
N/A
JHancock Disciplined Value Mid Cap R4
GAOSX22.46N/A
N/A
JPMorgan Global Allocation I
ICTTX16.31N/A
N/A
ICON Health and Information Tech Inv